GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2012

NMR Structural Biology Firm Signs First Drug Discovery Collaboration with AstraZeneca

  • Drug discovery and design optimization firm Conformetrix signed its first collaborative deal, with AstraZeneca. Under terms of the agreement the University of Manchester spin-out will apply its NMR-based structure-solving technology across AstraZeneca’s preclinical pipeline to improve lead discovery and hit identification. The platform will also be used to determine the bioactive conformations of naturally occurring ligands as templates for drug libraries. Conformetrix will receive an up-front payment, research funding, and potential milestones from AstraZeneca.

    Conformetrix claims its Molgyrate NMR platform can accurately solve the bioactive three-dimensional structures of molecules, independently of other techniques such as x-ray crystallography, within just weeks. The technique analyzes molecules in solution, and can be applied to a range of biological molecules including drug candidates, native peptide ligands, enzyme co-factors, oligonucleotides, and carbohydrates.

    The firm is exploiting the platform both for in-house discovery programs focused on identifying and optimizing novel small molecule drug candidates against key targets such as GPCRs and ion channels, as well as through collaborative projects.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?